Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
The most frequent type of acute lymphoblastic leukemia. Approximately 75% of cases occur in children under six years of age. This is a good prognosis leukemia. In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%. Approximately 80% of children appear to be cured. In the adult age group the complete remission rate is 60-85%. (WHO, 2001)
Biomarker and diagnostic research for precursor B-cell acute lymphoblastic leukemia has been reported in the published literature.
66 clinical trials registered, 20 recruiting. Interventions under study include drug therapy, biologic therapy, procedural interventions, and other interventions. Pipeline includes 10 PHASE3, 28 PHASE2, 23 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04546399](https://clinicaltrials.gov/study/NCT04546399) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 4:57 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) |
PHASE2 |
National Cancer Institute (NCI) |
RECRUITING |
[NCT05310591](https://clinicaltrials.gov/study/NCT05310591) | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence | PHASE1 | Assistance Publique - Hôpitaux de Paris | RECRUITING |
[NCT04746209](https://clinicaltrials.gov/study/NCT04746209) | Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | PHASE2 | Medical College of Wisconsin | RECRUITING |
[NCT07224100](https://clinicaltrials.gov/study/NCT07224100) | Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma | PHASE2 | University of Washington | RECRUITING |
[NCT06940960](https://clinicaltrials.gov/study/NCT06940960) | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | NA | Affiliated Hospital of Guangdong Medical University | RECRUITING |
139 publications have been identified in PubMed for precursor B-cell acute lymphoblastic leukemia. Research spans Case Report / Case Series (29%), Basic Science / Preclinical (17%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 41 | 29% |
Laboratory research | 24 | 17% |
Research summaries | 21 | 15% |
Clinical study results | 15 | 11% |
Disease patterns and progression | 12 | 9% |
New treatment approaches | 12 | 9% |
Testing and diagnosis research | 10 | 7% |
Other research | 4 | 3% |
Fry J (2026). [PMID: 42286409](https://pubmed.ncbi.nlm.nih.gov/42286409/). *Clin Transl Sci*. [Case Report / Case Series]
Singh K (2026). [PMID: 42156087](https://pubmed.ncbi.nlm.nih.gov/42156087/). *BMJ Case Rep*. [Case Report / Case Series]
Gupta P (2026). [PMID: 41764981](https://pubmed.ncbi.nlm.nih.gov/41764981/). *Curr Probl Cancer*. [Clinical Trial Publication]
Xiao D (2026). [PMID: 41979620](https://pubmed.ncbi.nlm.nih.gov/41979620/). *Clin Lab*. [Case Report / Case Series]
Insaurralde BA (2026). [PMID: 41979386](https://pubmed.ncbi.nlm.nih.gov/41979386/). *Arch Argent Pediatr*. [Epidemiology / Natural History]
Xue YJ (2026). [PMID: 42180060](https://pubmed.ncbi.nlm.nih.gov/42180060/). *Front Oncol*. [Basic Science / Preclinical]
Datta S (2026). [PMID: 41115238](https://pubmed.ncbi.nlm.nih.gov/41115238/). *Blood Adv*. [Review / Meta-Analysis]
Lameri M (2026). [PMID: 42239520](https://pubmed.ncbi.nlm.nih.gov/42239520/). *Front Pharmacol*. [Review / Meta-Analysis]
Cheriyan R (2026). [PMID: 41191824](https://pubmed.ncbi.nlm.nih.gov/41191824/). *J Pediatr Hematol Oncol*. [Case Report / Case Series]
Rysan H (2026). [PMID: 41490289](https://pubmed.ncbi.nlm.nih.gov/41490289/). *J Leukoc Biol*. [Basic Science / Preclinical]
AI-curated news mentioning precursor B-cell acute lymphoblastic leukemia
Updated Aug 1, 2026
A case study highlights an unusual cranial manifestation of B-cell precursor lymphoblastic lymphoma in a 10-year-old girl. This discovery may provide insights into the diverse presentations of this rare lymphoma subtype.
A case report highlights the spontaneous regression of B-cell acute lymphoblastic leukemia (B-ALL) associated with PAX5 alterations during relapse. This finding may provide insights into the mechanisms of leukemia regression and potential therapeutic targets.
A case report highlights an unusual presentation of Philadelphia chromosome positive B-cell acute lymphoblastic leukemia, featuring isolated osteolytic lesions at diagnosis. This finding may provide insights into the diverse manifestations of this leukemia subtype.
Real-world data confirms that inotuzumab ozogamicin significantly improves remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), with a 51.7% overall survival rate. The study highlights a 71.4% MRD-negative status in patients, facilitating further treatment options like ASCT or CAR T.